Boston Scientific to buy Nalu Medical for $533M

Big news in the medical device space! 🌟 Boston Scientific has announced its agreement to acquire Nalu Medical for $533M. Here's a quick rundown of what this means: - Strategic Growth: This acquisition aligns with Boston Scientific's strategy of expanding its neuromodulation portfolio. It's a move that continues their trend of growth through tuck-in deals. - Investment Pays Off: Having been an investor in Nalu since 2017, Boston Scientific is completing the purchase by acquiring the remaining equity they don't already own. This values Nalu at $600M. - Innovative Treatment: Nalu's neurostimulation system, which got FDA clearance in 2019, uses an implantable generator to ease chronic peripheral nerve pain. Imagine pain relief for those suffering from issues like shoulder or knee pain! - Future Prospects: Nalu is projected to generate over $60M in sales in 2025, with an anticipated growth rate of over 25% in 2026. The acquisition is expected to be slightly accretive starting in 2027 and increasingly so afterward. As a recruiter, it's exciting to see such dynamic developments in the industry! What do you think this means for the future of neuromodulation treatments? 🌐💡 #HealthcareInnovation #MedicalTechnology #BostonScientific

Big news in the medical device space! 🌟 Boston Scientific has announced its agreement to acquire Nalu Medical for $533M. Here's a quick rundown of what this means: - Strategic Growth: This acquisition aligns with Boston Scientific's strategy of expanding its neuromodulation portfolio. It's a move that continues their trend of growth through tuck-in deals. - Investment Pays Off: Having been an investor in Nalu since 2017, Boston Scientific is completing the purchase by acquiring the remaining equity they don't already own. This values Nalu at $600M. - Innovative Treatment: Nalu's neurostimulation system, which got FDA clearance in 2019, uses an implantable generator to ease chronic peripheral nerve pain. Imagine pain relief for those suffering from issues like shoulder or knee pain! - Future Prospects: Nalu is projected to generate over $60M in sales in 2025, with an anticipated growth rate of over 25% in 2026. The acquisition is expected to be slightly accretive starting in 2027 and increasingly so afterward. As a recruiter, it's exciting to see such dynamic developments in the industry! What do you think this means for the future of neuromodulation treatments? 🌐💡 #HealthcareInnovation #MedicalTechnology #BostonScientific

Boston Scientific said it will pay $533 million to buy the remaining equity in Nalu Medical, Inc., maker of a treatment for chronic peripheral nerve pain, as it continues its strategy of tuck-in acquisitions. https://lnkd.in/gJ-4hVur

Boston Scientific said it will pay $533 million to buy the remaining equity in Nalu Medical, Inc., maker of a treatment for chronic peripheral nerve pain, as it continues its strategy of tuck-in acquisitions. https://lnkd.in/gQWtVWww

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. Recent company milestones include 28 patients enrolled in first-in-human trial, 15 issued patents, breakthrough device designation by FDA. Efemoral Medical Compass Highlights: • Key Executives: Christopher Haig, Lewis Schwartz • Based in California, United States with ~4 employees • Potential Acquirers: Medtronic, Boston Scientific, Abbott • Currently raising a $20M Series B round • Selected to present at LSI USA ‘26 Company profiles contain proprietary insights from LSI events and Market Intelligence. Full profiles available in Compass.

Nalu Acquisition Boosts Boston Scientific: On 17 October 2025, Boston Scientific Corporation (NYSE: BSX) announced that it will acquire the remaining equity of Nalu Medical, Inc., a privately-held medical-technology company specialising in minimally invasive neurostimulation solutions for chronic peripheral-nerve pain.  This deal, valued at approximately US$533 million in cash, marks a strategic move that we’ll refer to as the “Nalu Acquisition”. Read more - https://lnkd.in/g5FmmEeU #NaluAcquisition #BostonScientific #NaluMedical #chronicpain #neurostimulation

It's official, ARCHIMED announces successful Acquisition of ZimVie Dental 🦷 Today at 09:00 EST it was announced that Lyon based, #MedTech focused Investment firm (€8bn fund), Archimed has completed its previously announced acquisition of ZimVie almost exactly 3 months since it was announced on July 21st this year. André-Michel Ballester, Managing Partner at Archimed stated; “ZimVie’s proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED’s mission to support world-class healthcare companies.” Archimed are currently boasting ~20% growth on average across it's portfolio groups, just some of it's portfolio include Natus Medical Incorporated, CEVA SANTE ANIMALE and Prollenium Medical Technologies Inc. I'm personally excited to see how this organization will perform outside of the Public Quarterly earnings calls to focus on long-term growth projects as a #Privately traded business, especially given it's long backstory from the merger of #zimmer and Biomet 3i in 2015 to become part of the #Orthopedic ~$8bn giant Zimmer Biomet and then span out in 2022 with the #Spine business, which was subsequently purchased by H.I.G. Capital, last year in 2024. Will this new investment now provide #ZimVie the opportunity to capitalize on their long-standing heritage? And how will they compete with some of the industry giants, including; Straumann Group, BioHorizons Camlog Group Global, Nobel Biocare & Dentsply Sirona. Looking forward to staying tuned on this one. #HiringMedTechsLeadingExecs | @Med|exec

Global medical technology company 4DMedical (ASX: 4DX) has released its FY25 Annual Report. It highlights the company’s many achievements from both a growth strategy and commercial partnerships perspective over the year, including: 📈 Strategic investment from Pro Medicus, strengthening balance sheet and distribution opportunities. 🫁 FDA clearance and U.S. reimbursement for CT:VQ™, the world’s first lung ventilation and perfusion software. 🌏 Global contract wins and renewals, driving momentum and uptake of 4DMedical’s SaaS products. 🤝 Reseller agreement with Philips across the U.S., unlocking a major commercial pathway. "I extend my thanks to our shareholders. We are grateful for your support including participation in the Share Placement and Share Purchase Plan early in 2025 and delighted to welcome new shareholders at this exciting point in our clinical and commercial growth." Ms Lil Bianchi, Non-Executive Director and Chair "I’m immensely proud that we secured FDA clearance for CT:VQ™: the first FDA cleared technology to provide perfusion imaging without an injected contrast agent. With CT:VQ™, any CT scanner can now be used to deliver non contrast lung imaging that assesses both ventilation (V) and perfusion (Q). In short, CT:VQ™ is a step change for lung health, addressing the clinical and logistical limitations of traditional nuclear V/Q imaging and unlocking a vast installed base of CT scanners, including at rural and smaller facilities that may not have nuclear infrastructure." Dr Andreas Fouras, Founder and CEO ASX announcement ⚡ https://lnkd.in/gC2-iYEV

𝐁𝐢𝐠𝐠𝐞𝐬𝐭 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 𝐃𝐞𝐚𝐥𝐬 – 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐟𝐨𝐫 𝐈𝐧𝐟𝐥𝐚𝐭𝐢𝐨𝐧 I recently wrote about the biggest deals in the ,#Pharma industry over the years. Here is also a look at the biggest deals in the ,#MedTech industry. The following are some of the biggest MedTech deals based on their present value: 🔹Medtronic's acquisition of Covidien (Medtronic Minimally Invasive Therapies Group) 🔹Boston Scientific's acquisition of 𝐆𝐮𝐢𝐝𝐚𝐧𝐭 🔹Abbott's acquisition of St. Jude Medical 🔹BD's acquisition of CR Bard 🔹Johnson & Johnson's acquisition of Synthes (was merged with existing DePuy DePuy Synthes) 🔹Siemens Healthineers's acquisition of Varian I will write more about some of these acquisitions in my coming posts. * Views and ideas are my own. The content I provide here is all public data intended to be educational only and is not financial advice. I encourage the readers to do their research #MedTech #MedicalDevices #Q22025 #HealthcareInnovation #MarketLeaders #SurgicalRobotics #InfographicDesign #VisualStorytelling #MedicalTechnology #LinkedInInsights #ABOKHATWAVisuals #DataDrivenDesign #CinematicInfographics

MEDTECH SCOOP: Buyout firms Blackstone and TPG are closing in on a deal to acquire Hologic, Inc. in what would be one of the largest private equity takeovers this year. Blackstone and TPG are discussing a transaction that values Hologic at more than $17 billion including debt. It could be announced as soon as next week, assuming no last-minute snags. Hologic is focused on women’s health, and develops diagnostic solutions for breast and cervical cancer, as well as infectious diseases like Covid-19. Story for Bloomberg News with Michelle Davis and David Carnevali: https://t.co/uqjxRa2R0T